Xeris Pharmaceuticals Inc. (XERS) Tops Q1 EPS by 1c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of $0.01, $0.01 better than the analyst estimate of $0.00. Revenue for the quarter came in at $83.13 million versus the consensus estimate of $83.7 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $380-390 million, versus the consensus of $383.3 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• TechCreate Group faces NYSE American delisting proceedings
• Nutrien warns shareholders about below-market mini-tender offer